Загрузка видео...

Не удалось загрузить видео

Возникла проблема при загрузке этого видео. Это может быть связано с временными проблемами сети или видео может быть недоступно.

На главную

🆕!! AI and atomic-level structure prediction are accelerating drug discovery — turning a slow, empirical search process into something closer to molecular engineering. Joshua Meier @_jackdent co-founders Chai Discovery chat their new bio foundation model, Chai-2. It enables zero-shot antibody discovery in a single 24-well plate — with a... show more

No Priors

6,416 subscribers

14,840 просмотров • 1 год назад •via X (Twitter)

Anya Rossi• Live Now

Private livecam show

Комментарии: 4

Фото профиля No Priors

No Priors1 год назад

Youtube, or anywhere you get your podcasts

Фото профиля Jake Mintz

Jake Mintz1 год назад

@saranormous @joshim5 @_jackdent @chaidiscovery Bullish on anything @_jackdent

Фото профиля Robert Youssef

Robert Youssef1 год назад

@joshim5 @_jackdent @chaidiscovery sounds great, but let's not forget it still comes down to testing. lab work won't vanish overnight.

Фото профиля Alex Prompter

Alex Prompter1 год назад

@joshim5 @_jackdent @chaidiscovery sounds like a game changer in drug discovery. compressing lab work into weeks is huge. curious to see how it unfolds in practice, though.

Похожие видео

We’re excited to introduce Chai-2, a major breakthrough in molecular design. Chai-2 enables zero-shot antibody discovery in a 24-well plate, exceeding previous SOTA by >100x. Thread👇

We’re excited to introduce Chai-2, a major breakthrough in molecular design. Chai-2 enables zero-shot antibody discovery in a 24-well plate, exceeding previous SOTA by >100x. Thread👇

Chai Discovery

709,164 просмотров • 1 год назад

New Unsupervised Learning with Joshua Meier @ NeurIPS (Chai Discovery) on how AI x drug discovery is starting to inflect and: - The 3 waves of AI biotech - How AI models think differently than chemists - Building "Photoshop for molecules" - Deciding what to open source

New Unsupervised Learning with Joshua Meier @ NeurIPS (Chai Discovery) on how AI x drug discovery is starting to inflect and: - The 3 waves of AI biotech - How AI models think differently than chemists - Building "Photoshop for molecules" - Deciding what to open source

Jacob Effron

12,351 просмотров • 10 месяцев назад

If you aren’t paying attention to the companies behind a new wave of AI-driven drug development, you may end up missing out on essential investment opportunities. One company that has caught my attention is Chai Discovery, co-founded in 2024 by Joshua Meier. After graduating from Harvard, Meier began working as a researcher at OpenAI during the development of GPT-1 and GPT-2. He then worked at Meta's generative biology group, where he co-led the development of ESM1, the first transformer protein-language model. Chai Discovery is currently one of the buzziest startups in AI drug development. In December, the company completed a Series B funding round, raising an additional $130 million at a valuation of $1.3 billion, cementing its unicorn status. Joshua shares his story on my Opening Bid Unfiltered podcast on Yahoo Finance, and what's next: Watch 📈Yahoo Finance: Listen: 🎙️Spotify: 🎧Apple:

If you aren’t paying attention to the companies behind a new wave of AI-driven drug development, you may end up missing out on essential investment opportunities. One company that has caught my attention is Chai Discovery, co-founded in 2024 by Joshua Meier. After graduating from Harvard, Meier began working as a researcher at OpenAI during the development of GPT-1 and GPT-2. He then worked at Meta's generative biology group, where he co-led the development of ESM1, the first transformer protein-language model. Chai Discovery is currently one of the buzziest startups in AI drug development. In December, the company completed a Series B funding round, raising an additional $130 million at a valuation of $1.3 billion, cementing its unicorn status. Joshua shares his story on my Opening Bid Unfiltered podcast on Yahoo Finance, and what's next: Watch 📈Yahoo Finance: Listen: 🎙️Spotify: 🎧Apple:

Brian Sozzi

35,107 просмотров • 4 месяцев назад

“In five years, doing drug design without AI will be like doing science without maths.” Max Jaderberg says the next frontier in drug discovery is collaboration with AI agents. You guide them. They search molecular space and return in hours with what would've taken humans weeks.

“In five years, doing drug design without AI will be like doing science without maths.” Max Jaderberg says the next frontier in drug discovery is collaboration with AI agents. You guide them. They search molecular space and return in hours with what would've taken humans weeks.

vitrupo

156,493 просмотров • 1 год назад

We asked Joshua Meier (Co-Founder Chai Discovery) about the future of AI in biotechnology. "We have scientists working for years trying to enable a certain class of drug program." "If we can use machine learning to jump to potential (drug) solutions, that could really push up the bar." "Everyone has to be an AI company now to compete. What’s that going to look like in biotech if you don't have access to a technology like this?"

We asked Joshua Meier (Co-Founder Chai Discovery) about the future of AI in biotechnology. "We have scientists working for years trying to enable a certain class of drug program." "If we can use machine learning to jump to potential (drug) solutions, that could really push up the bar." "Everyone has to be an AI company now to compete. What’s that going to look like in biotech if you don't have access to a technology like this?"

TBPN

44,460 просмотров • 1 год назад

Introducing LiteFold DeNovo. Generate hundreds of chemically viable ligands against any protein pocket, evaluate them in real time, and refine with our built in molecular editor. The problem: hit generation in drug discovery is slow, fragmented, and outsourced. With LiteFold DeNovo, it becomes interactive and instant. You can also fragment grow base generated molecules, iterate, and soon run molecular dynamics to test stability. Docking and large scale screening are on the way. When we said we’re building the AI first lab for drug discovery, we meant it. Super excited to what's coming next. Codename: Rosalind Try LiteFold DeNovo today. It’s free. Links in the comments.

Introducing LiteFold DeNovo. Generate hundreds of chemically viable ligands against any protein pocket, evaluate them in real time, and refine with our built in molecular editor. The problem: hit generation in drug discovery is slow, fragmented, and outsourced. With LiteFold DeNovo, it becomes interactive and instant. You can also fragment grow base generated molecules, iterate, and soon run molecular dynamics to test stability. Docking and large scale screening are on the way. When we said we’re building the AI first lab for drug discovery, we meant it. Super excited to what's coming next. Codename: Rosalind Try LiteFold DeNovo today. It’s free. Links in the comments.

Anindya

23,157 просмотров • 10 месяцев назад

"We have this long term vision of turning biology from something which is trial and error and experimental and make it something that looks more like an engineering discipline in the next century." New Episode with Jack Dent ! 0:00 Intro 02:28 Inside Stripe w/ Patrick Collison, at <100 People 08:45 Sam Altman role in Chai Discovery origin 16:20 Chai-2 Antibody Breakthrough 19:24 Approaching biology as an engineering problem 24:45 Using AI models to treat people on an individual scale 26:52 Robotics in labs 27:22 Pharma industry today 29:49 The clinical trial bottleneck 32:53 Personalized biology models & cancer vaccines 36:24 Longevity, peptides, and trillion-dollar drugs 39:02 Does it matter that the government cut exploratory science grants? 41:00 What next-gen Chai models will do 42:08 Can frontier AI labs build this themselves? 43:26 Biology is hard

"We have this long term vision of turning biology from something which is trial and error and experimental and make it something that looks more like an engineering discipline in the next century." New Episode with Jack Dent ! 0:00 Intro 02:28 Inside Stripe w/ Patrick Collison, at <100 People 08:45 Sam Altman role in Chai Discovery origin 16:20 Chai-2 Antibody Breakthrough 19:24 Approaching biology as an engineering problem 24:45 Using AI models to treat people on an individual scale 26:52 Robotics in labs 27:22 Pharma industry today 29:49 The clinical trial bottleneck 32:53 Personalized biology models & cancer vaccines 36:24 Longevity, peptides, and trillion-dollar drugs 39:02 Does it matter that the government cut exploratory science grants? 41:00 What next-gen Chai models will do 42:08 Can frontier AI labs build this themselves? 43:26 Biology is hard

Sabrina Halper

37,886 просмотров • 1 месяц назад

We live in a golden age of biology. So why are people still dying from disease? Because discovery and development move slower than they should. Today, we’re partnering with Incyte to change that. Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. Incyte will be the first company to deploy it across their pipeline. Work that used to take a team of scientists months now happens in weeks. Patients can't wait, and neither can we.

We live in a golden age of biology. So why are people still dying from disease? Because discovery and development move slower than they should. Today, we’re partnering with Incyte to change that. Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. Incyte will be the first company to deploy it across their pipeline. Work that used to take a team of scientists months now happens in weeks. Patients can't wait, and neither can we.

Sam Rodriques

7,024,618 просмотров • 1 месяц назад

How can generative AI and Robotics help advance drug discovery？ 🚀 Excited to introduce LUMI-lab! A foundation model-driven Self-Driving Lab (SDL) for autonomous ionizable lipid discovery in mRNA delivery 🤖🔍 🔬 What is LUMI-lab? LUMI-lab integrates molecular foundation models with autonomous robotic experiments to efficiently explore new LNPs (lipid nanoparticles, mRNA delivery vehicles) with minimal wet-lab data. 🔥 Key Highlights: - 🧠 Foundation model trained on 28M molecules using a three-step strategy: - Unsupervised pretraining to capture broad molecular knowledge - Continual pretraining to specialize in lipid-like molecules - Active learning fine-tuning within a closed-loop experimental system - 🤖 1,700+ new LNPs synthesized & tested across 10 iterative cycles - 🧪 Brominated lipids autonomously identified as a novel structural feature that enhances mRNA transfection—an insight previously unrecognized in LNP design - 🏆 20.3% in vivo CRISPR gene editing efficiency in lung epithelial cells—the highest reported for inhaled LNPs 🚀 Why it matters? LNPs are the backbone of mRNA therapeutics, yet discovery has been slow due to data scarcity. LUMI-lab shows that AI-powered autonomous labs can accelerate mRNA delivery innovation🚀💡 🌐 Beyond mRNA drugs, LUMI-lab exemplifies a scalable framework for AI-driven molecular discovery, pushing boundaries in material science & drug delivery. 📜 Read the preprint: 🔗 💻 Code available on GitHub: 🔗 #AI #DrugDiscovery #mRNA #LNP #SyntheticBiology 🙏 A huge team effort behind this work, with special appreciation to Bowen LI for driving the project. Kudos to Haotian Cui, Yue Xu, Kuan Pang, Gen Li, and Bettycat567!

How can generative AI and Robotics help advance drug discovery？ 🚀 Excited to introduce LUMI-lab! A foundation model-driven Self-Driving Lab (SDL) for autonomous ionizable lipid discovery in mRNA delivery 🤖🔍 🔬 What is LUMI-lab? LUMI-lab integrates molecular foundation models with autonomous robotic experiments to efficiently explore new LNPs (lipid nanoparticles, mRNA delivery vehicles) with minimal wet-lab data. 🔥 Key Highlights: - 🧠 Foundation model trained on 28M molecules using a three-step strategy: - Unsupervised pretraining to capture broad molecular knowledge - Continual pretraining to specialize in lipid-like molecules - Active learning fine-tuning within a closed-loop experimental system - 🤖 1,700+ new LNPs synthesized & tested across 10 iterative cycles - 🧪 Brominated lipids autonomously identified as a novel structural feature that enhances mRNA transfection—an insight previously unrecognized in LNP design - 🏆 20.3% in vivo CRISPR gene editing efficiency in lung epithelial cells—the highest reported for inhaled LNPs 🚀 Why it matters? LNPs are the backbone of mRNA therapeutics, yet discovery has been slow due to data scarcity. LUMI-lab shows that AI-powered autonomous labs can accelerate mRNA delivery innovation🚀💡 🌐 Beyond mRNA drugs, LUMI-lab exemplifies a scalable framework for AI-driven molecular discovery, pushing boundaries in material science & drug delivery. 📜 Read the preprint: 🔗 💻 Code available on GitHub: 🔗 #AI #DrugDiscovery #mRNA #LNP #SyntheticBiology 🙏 A huge team effort behind this work, with special appreciation to Bowen LI for driving the project. Kudos to Haotian Cui, Yue Xu, Kuan Pang, Gen Li, and Bettycat567!

Bo Wang

27,567 просмотров • 1 год назад

ReaSyn is helping to revolutionize drug discovery 🔬 Our new generative AI predicts synthetic pathways for molecules using step-by-step reasoning accelerating drug discovery and scientific breakthroughs. Read more and try the code ➡️ #NVIDIAResearch

ReaSyn is helping to revolutionize drug discovery 🔬 Our new generative AI predicts synthetic pathways for molecules using step-by-step reasoning accelerating drug discovery and scientific breakthroughs. Read more and try the code ➡️ #NVIDIAResearch

NVIDIA AI Developer

25,451 просмотров • 9 месяцев назад

"The future is really bright in AI and drug discovery." Sean McClain, Founder and CEO of Absci, shared the CES stage with healthcare leaders to illustrate how the compute partnership with AMD has scaled their ability to screen over a million drugs in one single day, resulting in better models for drug discovery.

"The future is really bright in AI and drug discovery." Sean McClain, Founder and CEO of Absci, shared the CES stage with healthcare leaders to illustrate how the compute partnership with AMD has scaled their ability to screen over a million drugs in one single day, resulting in better models for drug discovery.

AMD

15,343 просмотров • 4 месяцев назад

🔬 New Science pod with CuspAI! We are entering a new era where materials science and discovery is transitioning from slow, manual experimentation, to a high-speed search problem powered by generative AI and "physics processing units." Max Welling argues that the foundation of all modern technology—from GPUs to climate solutions—is a materials problem, and that unifying the mathematics of stochastic thermodynamics with generative AI will unlock a new paradigm of automated scientific discovery.

🔬 New Science pod with CuspAI! We are entering a new era where materials science and discovery is transitioning from slow, manual experimentation, to a high-speed search problem powered by generative AI and "physics processing units." Max Welling argues that the foundation of all modern technology—from GPUs to climate solutions—is a materials problem, and that unifying the mathematics of stochastic thermodynamics with generative AI will unlock a new paradigm of automated scientific discovery.

Latent.Space

20,343 просмотров • 4 месяцев назад

Armed with a new eyewitness account and cutting-edge tech, Josh heads to Micronesia to dive deep in search of a lost P-47 Thunderbolt. Don’t miss it — TONIGHT at 9p on Discovery! #ExpeditionUnknown

Armed with a new eyewitness account and cutting-edge tech, Josh heads to Micronesia to dive deep in search of a lost P-47 Thunderbolt. Don’t miss it — TONIGHT at 9p on Discovery! #ExpeditionUnknown

Discovery

11,714 просмотров • 11 месяцев назад

They're trying to fix up a vintage sport fury with hopes of selling it for some BIG cash. Catch a new #FilthyFortunes tonight at 10P on Discovery

They're trying to fix up a vintage sport fury with hopes of selling it for some BIG cash. Catch a new #FilthyFortunes tonight at 10P on Discovery

Discovery

13,239 просмотров • 3 месяцев назад

Anthropic CEO Dario Amodei says AI could increase the rate of discovery in biology by 100x, compressing the total amount of progress that occurred in the 20th and 21st centuries to just a few years

Anthropic CEO Dario Amodei says AI could increase the rate of discovery in biology by 100x, compressing the total amount of progress that occurred in the 20th and 21st centuries to just a few years

Tsarathustra

593,945 просмотров • 1 год назад

Boltz-2 was released recently. It is an Open Source protein-ligand co-folding model, which means it can predict the structure of a protein along with the ligand. It has various applications from drug discovery to protein design. I thought why not make a OSS web app for it.

Boltz-2 was released recently. It is an Open Source protein-ligand co-folding model, which means it can predict the structure of a protein along with the ligand. It has various applications from drug discovery to protein design. I thought why not make a OSS web app for it.

Ravi Sharma

43,890 просмотров • 1 год назад

What could scaling unlock for biology? Introducing ProGen3- our next AI foundation models for protein generation. We develop compute-optimal scaling laws up to 46B parameters on 1.5T tokens with real evidence in the wet lab. +we solve a new set of challenges for drug discovery

What could scaling unlock for biology? Introducing ProGen3- our next AI foundation models for protein generation. We develop compute-optimal scaling laws up to 46B parameters on 1.5T tokens with real evidence in the wet lab. +we solve a new set of challenges for drug discovery

Ali Madani

80,642 просмотров • 1 год назад

Demis Hassabis just described the exact architecture he is building to cure all human disease and said the breakthrough will not come gradually. It will hit all at once. He is building a full platform to do it. Think of it as a dozen AlphaFold-level models, each one covering a different step in the drug discovery process, all stitched together into a single engine that can be pointed at almost any disease area on earth. AlphaFold solved protein structure. It then folded 200 million proteins in a single year. Hassabis is now building the equivalent of that for every other step like protein interactions, molecular binding, toxicity prediction, drug design, and clinical stratification. Each one its own AlphaFold. All of them connected. He is already testing it on disease profiles in pre-clinical stages right now. Most biotech analysts still model drug discovery timelines in decades. McKinsey published a report estimating AI could reduce discovery timelines by 25 to 50 percent. Hassabis is not describing a 25 percent improvement. He is describing a complete replacement of the process. Do not expect a slow drip of results. Expect nothing for a few years and then a sudden explosion where everything works at once. Demis is running the same play. At a scale that makes AlphaFold look like a warm-up act. (Watch the full interview on YouTube at Two Minute Papers channel)

Demis Hassabis just described the exact architecture he is building to cure all human disease and said the breakthrough will not come gradually. It will hit all at once. He is building a full platform to do it. Think of it as a dozen AlphaFold-level models, each one covering a different step in the drug discovery process, all stitched together into a single engine that can be pointed at almost any disease area on earth. AlphaFold solved protein structure. It then folded 200 million proteins in a single year. Hassabis is now building the equivalent of that for every other step like protein interactions, molecular binding, toxicity prediction, drug design, and clinical stratification. Each one its own AlphaFold. All of them connected. He is already testing it on disease profiles in pre-clinical stages right now. Most biotech analysts still model drug discovery timelines in decades. McKinsey published a report estimating AI could reduce discovery timelines by 25 to 50 percent. Hassabis is not describing a 25 percent improvement. He is describing a complete replacement of the process. Do not expect a slow drip of results. Expect nothing for a few years and then a sudden explosion where everything works at once. Demis is running the same play. At a scale that makes AlphaFold look like a warm-up act. (Watch the full interview on YouTube at Two Minute Papers channel)

Ihtesham Ali

100,472 просмотров • 8 дней назад

GPT-5.4 helped drive a medicinal chemistry project from literature review to a validated experimental result. Paired with Maria AI and specialized lab, the model proposed an unexpected way to improve a widely used reaction in drug discovery.

GPT-5.4 helped drive a medicinal chemistry project from literature review to a validated experimental result. Paired with Maria AI and specialized lab, the model proposed an unexpected way to improve a widely used reaction in drug discovery.

OpenAI

479,622 просмотров • 14 дней назад

Cool product for chai lovers. I always end up babysitting chai on the stove to stop it from boiling over, and half the time I still make a mess. The Loka solves that in a clever way and makes great chai. $150, but it is a really nice product

Cool product for chai lovers. I always end up babysitting chai on the stove to stop it from boiling over, and half the time I still make a mess. The Loka solves that in a clever way and makes great chai. $150, but it is a really nice product

Sheel Mohnot

137,863 просмотров • 4 месяцев назад